Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Apr;71(4):2913–2920. doi: 10.1128/jvi.71.4.2913-2920.1997

Coexistence in lactate dehydrogenase-elevating virus pools of variants that differ in neuropathogenicity and ability to establish a persistent infection.

Z Chen 1, R R Rowland 1, G W Anderson 1, G A Palmer 1, P G Plagemann 1
PMCID: PMC191418  PMID: 9060649

Abstract

Neuropathogenic isolates of lactate dehydrogenase-elevating virus (LDV) differ from nonneuropathogenic isolates in their unique ability to infect anterior horn neurons of immunosuppressed C58 and AKR mice and cause paralytic disease (age-dependent poliomyelitis [ADPM]). However, we and others have found that neuropathogenic LDVs fail to retain their neuropathogenicity during persistent infections of both ADPM-susceptible and nonsusceptible mice. On the basis of a segment in open reading frame 2 that differs about 60% between the neuropathogenic LDV-C and the nonneuropathogenic LDV-P, we have developed a reverse transcription-PCR assay that distinguishes between the genomes of the two LDVs and detects as little as 10 50% infectious doses (ID50) of LDV. With this assay, we found that LDV-P and LDV-C coexist in most available pools of LDV-C and LDV-P. For example, various plasma pools of 10(9.5) ID50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml. Injection of such an LDV-C pool into mice of various strains resulted in the rapid displacement in the circulation of LDV-C by LDV-P as the predominant LDV, but LDV-C also persisted in the mice at a low level along with LDV-P. We have freed LDV-C of LDV-P by endpoint dilution (LDV-C-EPD). LDV-C-EPD infected mice as efficiently as did LDV-P, but its level of viremia during the persistent phase was only 1/10,000 that observed for LDV-P. LDV-permissive macrophages accumulated and supported the efficient replication of superinfecting LDV-P. Therefore, although neuropathogenic LDVs possess the unique ability to infect anterior horn neurons of ADPM-susceptible mice, they exhibit a reduced ability to establish a persistent infection in peripheral tissues of mice regardless of the strain. The specific suppression of LDV-C replication in persistently infected mice is probably due in part to a more efficient neutralization of LDV-C than LDV-P by antibodies to the primary envelope glycoprotein, VP-3P. Both neuropathogenicity and the higher sensitivity to antibody neutralization correlated with the absence of two of three N-linked polylactosaminoglycan chains on the ca. 30-amino-acid ectodomain of VP-3P, which seems to carry the neutralization epitope(s) and forms part of the virus receptor attachment site.

Full Text

The Full Text of this article is available as a PDF (784.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson G. W., Even C., Rowland R. R., Palmer G. A., Harty J. T., Plagemann P. G. C58 and AKR mice of all ages develop motor neuron disease after lactate dehydrogenase-elevating virus infection but only if antiviral immune responses are blocked by chemical or genetic means or as a result of old age. J Neurovirol. 1995 Sep;1(3-4):244–252. doi: 10.3109/13550289509114020. [DOI] [PubMed] [Google Scholar]
  2. Anderson G. W., Palmer G. A., Rowland R. R., Even C., Plagemann P. G. Infection of central nervous system cells by ecotropic murine leukemia virus in C58 and AKR mice and in in utero-infected CE/J mice predisposes mice to paralytic infection by lactate dehydrogenase-elevating virus. J Virol. 1995 Jan;69(1):308–319. doi: 10.1128/jvi.69.1.308-319.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson G. W., Palmer G. A., Rowland R. R., Even C., Plagemann P. G. Lactate dehydrogenase-elevating virus entry into the central nervous system and replication in anterior horn neurons. J Gen Virol. 1995 Mar;76(Pt 3):581–592. doi: 10.1099/0022-1317-76-3-581. [DOI] [PubMed] [Google Scholar]
  4. Anderson G. W., Rowland R. R., Palmer G. A., Even C., Plagemann P. G. Lactate dehydrogenase-elevating virus replication persists in liver, spleen, lymph node, and testis tissues and results in accumulation of viral RNA in germinal centers, concomitant with polyclonal activation of B cells. J Virol. 1995 Aug;69(8):5177–5185. doi: 10.1128/jvi.69.8.5177-5185.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brinton-Darnell M., Plagemann P. G. Structure and chemical-physical characteristics of lactate dehydrogenase-elevating virus and its RNA. J Virol. 1975 Aug;16(2):420–433. doi: 10.1128/jvi.16.2.420-433.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cafruny W. A., Chan S. P., Harty J. T., Yousefi S., Kowalchyk K., McDonald D., Foreman B., Budweg G., Plagemann P. G. Antibody response of mice to lactate dehydrogenase-elevating virus during infection and immunization with inactivated virus. Virus Res. 1986 Sep;5(4):357–375. doi: 10.1016/0168-1702(86)90029-8. [DOI] [PubMed] [Google Scholar]
  7. Cafruny W. A., Strancke C. R., Kowalchyk K., Plagemann P. G. Replication of lactate dehydrogenase-elevating virus in C58 mice and quantification of antiviral antibodies and of tissue virus levels as a function of development of paralytic disease. J Gen Virol. 1986 Jan;67(Pt 1):27–37. doi: 10.1099/0022-1317-67-1-27. [DOI] [PubMed] [Google Scholar]
  8. Chen Z., Kuo L., Rowland R. R., Even C., Faaberg K. S., Plagemann P. G. Sequences of 3' end of genome and of 5' end of open reading frame 1a of lactate dehydrogenase-elevating virus and common junction motifs between 5' leader and bodies of seven subgenomic mRNAs. J Gen Virol. 1993 Apr;74(Pt 4):643–659. doi: 10.1099/0022-1317-74-4-643. [DOI] [PubMed] [Google Scholar]
  9. Dockter J., Evans C. F., Tishon A., Oldstone M. B. Competitive selection in vivo by a cell for one variant over another: implications for RNA virus quasispecies in vivo. J Virol. 1996 Mar;70(3):1799–1803. doi: 10.1128/jvi.70.3.1799-1803.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Even C., Rowland R. R., Plagemann P. G. Cytotoxic T cells are elicited during acute infection of mice with lactate dehydrogenase-elevating virus but disappear during the chronic phase of infection. J Virol. 1995 Sep;69(9):5666–5676. doi: 10.1128/jvi.69.9.5666-5676.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Faaberg K. S., Even C., Palmer G. A., Plagemann P. G. Disulfide bonds between two envelope proteins of lactate dehydrogenase-elevating virus are essential for viral infectivity. J Virol. 1995 Jan;69(1):613–617. doi: 10.1128/jvi.69.1.613-617.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Faaberg K. S., Palmer G. A., Even C., Anderson G. W., Plagemann P. G. Differential glycosylation of the ectodomain of the primary envelope glycoprotein of two strains of lactate dehydrogenase-elevating virus that differ in neuropathogenicity. Virus Res. 1995 Dec;39(2-3):331–340. doi: 10.1016/0168-1702(95)00088-7. [DOI] [PubMed] [Google Scholar]
  13. Faaberg K. S., Plagemann P. G. The envelope proteins of lactate dehydrogenase-elevating virus and their membrane topography. Virology. 1995 Oct 1;212(2):512–525. doi: 10.1006/viro.1995.1509. [DOI] [PubMed] [Google Scholar]
  14. Fauci A. S. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993 Nov 12;262(5136):1011–1018. doi: 10.1126/science.8235617. [DOI] [PubMed] [Google Scholar]
  15. Godeny E. K., Chen L., Kumar S. N., Methven S. L., Koonin E. V., Brinton M. A. Complete genomic sequence and phylogenetic analysis of the lactate dehydrogenase-elevating virus (LDV). Virology. 1993 Jun;194(2):585–596. doi: 10.1006/viro.1993.1298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harty J. T., Plagemann P. G. Monoclonal antibody protection from age-dependent poliomyelitis: implications regarding the pathogenesis of lactate dehydrogenase-elevating virus. J Virol. 1990 Dec;64(12):6257–6262. doi: 10.1128/jvi.64.12.6257-6262.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Holland J. J., De La Torre J. C., Steinhauer D. A. RNA virus populations as quasispecies. Curr Top Microbiol Immunol. 1992;176:1–20. doi: 10.1007/978-3-642-77011-1_1. [DOI] [PubMed] [Google Scholar]
  18. Kowalchyk K., Plagemann P. G. Cell surface receptors for lactate dehydrogenase-elevating virus on subpopulation of macrophages. Virus Res. 1985 Apr;2(3):211–229. doi: 10.1016/0168-1702(85)90010-3. [DOI] [PubMed] [Google Scholar]
  19. Lawrence C. B., Goldman D. A. Definition and identification of homology domains. Comput Appl Biosci. 1988 Mar;4(1):25–33. doi: 10.1093/bioinformatics/4.1.25. [DOI] [PubMed] [Google Scholar]
  20. Martinez D., Brinton M. A., Tachovsky T. G., Phelps A. H. Identification of lactate dehydrogenase-elevating virus as the etiological agent of genetically restricted, age-dependent polioencephalomyelitis of mice. Infect Immun. 1980 Mar;27(3):979–987. doi: 10.1128/iai.27.3.979-987.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Murphy W. H., Nawrocki J. F., Pease L. R. Age-dependent paralytic viral infection in C58 mice: possible implications in human neurologic disease. Prog Brain Res. 1983;59:291–303. doi: 10.1016/S0079-6123(08)63874-1. [DOI] [PubMed] [Google Scholar]
  22. Nawrocki J. F., Pease L. R., Murphy W. H. Etiologic role of lactic dehydrogenase virus infection in an age-dependent neuroparalytic disease in C58 mice. Virology. 1980 May;103(1):259–264. doi: 10.1016/0042-6822(80)90147-6. [DOI] [PubMed] [Google Scholar]
  23. Palmer G. A., Kuo L., Chen Z., Faaberg K. S., Plagemann P. G. Sequence of the genome of lactate dehydrogenase-elevating virus: heterogenicity between strains P and C. Virology. 1995 Jun 1;209(2):637–642. doi: 10.1006/viro.1995.1296. [DOI] [PubMed] [Google Scholar]
  24. Plagemann P. G., Moennig V. Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. Adv Virus Res. 1992;41:99–192. doi: 10.1016/S0065-3527(08)60036-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Plagemann P. G., Rowland R. R., Even C., Faaberg K. S. Lactate dehydrogenase-elevating virus: an ideal persistent virus? Springer Semin Immunopathol. 1995;17(2-3):167–186. doi: 10.1007/BF00196164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Revision of the taxonomy of the Coronavirus, Torovirus and Arterivirus genera. Arch Virol. 1994;135(1-2):227–237. doi: 10.1007/BF01309782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rowson K. E., Mahy B. W. Lactic dehydrogenase virus. Virol Monogr. 1975;(13):1–121. doi: 10.1007/978-3-7091-8378-6_1. [DOI] [PubMed] [Google Scholar]
  28. Stroop W. G., Brinton M. A. Mouse strain-specific central nervous system lesions associated with lactate dehydrogenase-elevating virus infection. Lab Invest. 1983 Sep;49(3):334–345. [PubMed] [Google Scholar]
  29. Villarete L., Somasundaram T., Ahmed R. Tissue-mediated selection of viral variants: correlation between glycoprotein mutation and growth in neuronal cells. J Virol. 1994 Nov;68(11):7490–7496. doi: 10.1128/jvi.68.11.7490-7496.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES